Incident Report
Subform I: General Information
1. Report Type.
New incident report
Incident Report Number: 2024-1607
2. Registrant Information.
Registrant Reference Number: FMC-60264
Registrant Name (Full Legal Name no abbreviations): FMC of Canada Limited
Address: 6755 Mississauga Road, Suite 204
City: Mississauga
Prov / State: Ontario
Country: Canada
Postal Code: L5N7Y2
3. Select the appropriate subform(s) for the incident.
Scientific Study
4. Date registrant was first informed of the incident.
5. Location of incident.
6. Date incident was first observed.
Product Description
7. a) Provide the active ingredient and, if available, the registration number and product name (include all tank mixes). If the product is not registered provide a submission number.
Active(s)
PMRA Registration No. 28809
PMRA Submission No.
EPA Registration No. 279-9582
Product Name: Thifensulfuron 50 SG MUP
PMRA Registration No. 29442
PMRA Submission No.
EPA Registration No. 279-9580
Product Name: FMC Tribenuron-methyl Technical Herbicide
7. b) Type of formulation.
Application Information
8. Product was applied?
Unknown
9. Application Rate.
10. Site pesticide was applied to (select all that apply).
11. Provide any additional information regarding application (how it was applied, amount applied, the size of the area treated etc).
To be determined by Registrant
12. In your opinion, was the product used according to the label instructions?
Unknown
Subform VII: Scientific Study
1. Study Reference
Title Thifensulfuron Methyl 50SG/Tribenuron Methyl 50SG (Q9B30) (1:3): A Blend of Paste Extruded Granules (12.5% + 37.5% Active) plus KG691 Surfactant: Acute Contact and Oral Toxicity to Bumblebees (Bombus terrestris L.) in the Laboratory
Date 24-JAN-24
2. a) Is an extension needed to translate the document?
No
3. Type of incident identified in the study
Increased health or environmental risk
4. Describe the incident identified in the study (e.g. study demonstrates an increased risk to non-Hodgkin's Lymphoma after exposure to pesticide X)
FMC believes endpoints reached in these studies are reportable.
5. a) Was the study discontinued before completion?
No
5. b) Provide the reason for discontinuation
6. If the study is ongoing, what is the expected completion date?
For Registrant use only
7. Provide supplemental information here